Securities Code: 002294 Securities Abbreviation: Lifetai Number: 2026-032 Shenzhen Lifetai Pharmaceutical Co., Ltd. 2025 Annual Report on the Storage, Management, and Use of Raised Funds
The company and all members of the board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
In accordance with the "Supervision Measures for the Management of Raised Funds by Listed Companies" issued by the China Securities Regulatory Commission and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 1 - Standardized Operation of Main Board Listed Companies" issued by the Shenzhen Stock Exchange, Shenzhen Lifetai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has compiled this special report on the storage, management, and use of raised funds as of December 31, 2025.
I. Basic情况 of Raised Funds
-
Amount of Raised Funds and Time of Receipt As approved by the China Securities Regulatory Commission's document "Approval for Shenzhen Lifetai Pharmaceutical Co., Ltd. to Issue Shares Privately" (Zheng Jian Xu Ke [2021] No. 663), the Company issued 68,800,535 ordinary shares of RMB 1 par value to specific investors at an issue price of RMB 28.37 per share. The total raised funds amounted to RMB 1,951,871,200. After deducting non-tax issuance expenses of RMB 19,805,500, the net amount of raised funds was RMB 1,932,065,700. These raised funds were all received on May 24, 2021, and were verified and confirmed by the capital verification report (Da Xin Yan Zi [2021] No. 5-10001) issued by Da Xin Certified Public Accountants (Special General Partnership).
-
Amount of Raised Funds Used in 2025 and Year-End Balance (1) Amount Used in Previous Years As of December 31, 2024, the Company had cumulatively invested RMB 1,099,389,200 in raised funds, with a balance of RMB 954,299,000 in the raised funds account.
(2) Amount of Raised Funds Used in 2025 As of December 31, 2025, the Company had cumulatively invested RMB 1,310,995,700 in raised funds. Of this amount, RMB 7,374.65 million was invested in raised fund projects during the reporting period, and RMB 13,786.00 million (including interest income of RMB 2,120.82 million) was permanently supplemented to working capital.
(3) Year-End Balance of Raised Funds in 2025 As of December 31, 2025, the balance in the Company's raised funds account was RMB 76,838.93 million. During the reporting period, the raised funds account accumulated interest income of RMB 2,570.20 million (including cash management income of RMB 2,528.68 million and current deposit interest income of RMB 41.52 million), and paid handling fees of RMB 0.52 million.
| Unit: Ten Thousand Yuan | |
|---|---|
| Balance of raised funds as of December 31, 2024 | 95,429.90 |
| Less: Funds invested in raised fund projects during the reporting period | 7,374.65 |
| Less: Transfer of completed project surplus funds (including interest income) | 13,786.00 |
| Less: Handling fees paid during the reporting period | 0.52 |
| Plus: Interest income during the reporting period | 2,570.20 |
| Balance of raised funds as of December 31, 2025 | 76,838.93 |
Note: If there are discrepancies between the total and the sum of individual items in this report, it is due to rounding to the nearest decimal place.